https://www.insideprecisionmedicine.com/topics/oncology/first-blood-test-for-dozens-of-hereditary-cancers-approved-by-fda/ clinicalomicsprowebdirectory * News * Topics + Informatics + Molecular Dx + Patient Care + Oncology + Precision Medicine + Translational Research * Magazine + Current Issue + Past Issues + Supplements + Subscribe * Marketplace + Translational Research + Molecular Diagnostics + Oncology/Therapeutics + Healthcare Informatics * Subscribe + Get Inside Precision Medicine Magazine + Get Inside Precision Medicine eNewsletters * Multimedia + eBooks + Webinars + Virtual Event + Learning Labs + Podcasts + Inside Precision Medicine Live Search [ ] * Update Preferences Sign in Welcome! Log into your account [ ]your username [ ]your password [Login] Forgot your password? Get help Create an account Privacy Policy Create an account Welcome! Register for an account [ ]your email [ ]your username [Register] A password will be e-mailed to you. Privacy Policy Password recovery Recover your password [ ]your email [Send My Password] A password will be e-mailed to you. Inside Precision Medicine Inside Precision Medicine Inside Precision Medicine Inside Precision Medicine * News + Black prostate cancer patients views test results. Molecular Dx Precision Medicine Navigators Increase Rates of Genetic Testing in Black Prostate... Close up of human biotechnologist testing testing blood for cancer in a laboratory Molecular Dx First Blood Test for Dozens of Hereditary Cancers Approved by FDA Pharmaceuticals regulations concept News & Features FDA Begins Program to Speed Up Development of Rare Disease Therapeutics An illustration of SARS-CoV-2 virus particles next to a diseased looking heart, to represent cardiovascular complications after COVID-19 Coronavirus COVID-19 Causes Heart Attack and Stroke by Inflaming Arterial Plaque Medicine Pills News & Features EEG-Based Model Predicts Antidepressant Response * Topics + Informatics + Molecular Dx + Patient Care + Oncology + Precision Medicine + Translational Research * Magazine + Current Issue + Past Issues + Supplements + Subscribe * Marketplace + Translational Research + Molecular Diagnostics + Oncology/Therapeutics + Healthcare Informatics * Subscribe + Get Inside Precision Medicine Magazine + Get Inside Precision Medicine eNewsletters * Multimedia + eBooks + Webinars + Virtual Event + Learning Labs + Podcasts + Inside Precision Medicine Live [ ][Search] Inside Precision Medicine Molecular Dx - Oncology - Patient Care - Precision Medicine First Blood Test for Dozens of Hereditary Cancers Approved by FDAbbbb First Blood Test for Dozens of Hereditary Cancers Approved by FDA October 2, 2023 Share Facebook Twitter Linkedin ReddIt Email Close up of human biotechnologist testing testing blood for cancer in a laboratoryCredit: Nadasaki / Getty Images The FDA has approved the first blood test that can help identify hundreds of potentially cancer-associated hereditary variants. The Invitae Common Hereditary Cancers Panel evaluates a blood sample to identify DNA variants in 47 genes associated with an elevated risk of developing certain types of cancer. The agency has granted de novo marketing authorization for the test, which creates a new regulatory classification. Subsequent devices of the same type may go through FDA's 510(k) premarket process for marketing approval. Along with this De Novo authorization, the FDA is establishing special controls that define the requirements related to labeling and performance testing. For example, accuracy for reporting of substitutions, insertions/deletions, and copy number variants must be >=99.0% for positive agreement and >=99.9% for negative agreement with a validated orthogonal method. "This [Invitae's] test can assess multiple genes in a single test by using next-generation sequencing, which has proven helpful in providing insight into genetic variants with sensitivity and speed," said Jeff Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health. According to the Centers for Disease Control and Prevention (CDC), there are more than 100 different types of cancer, which is the second leading cause of death in the US behind heart disease. Meanwhile, the number of hereditary cancer variants identified has steadily increased, as well as the number of tests for them. But there is not much of an increase in testing for these. In a recent presentation at ASCO, a research team at University of Vermont Medical Center partnered with Invitae to test patients with advanced cancer early and then offer genetic counseling if a pathogenic genetic variant was identified. Patients and healthcare providers were given a survey to gauge their satisfaction with the streamlined testing process. More than 94% of patients appreciated having undergone testing during an existing appointment and 82% of participants felt confident that they understood the results of their test. For Invitae's prescription test, the specimen is collected at the point of care, such as a doctor's office, and sent to a laboratory for testing. The clinical interpretation of the variants is based on evidence from published literature, public databases, prediction programs, and the company's internal curated variants database using variant interpretation criteria based on those established by professional organizations or accredited boards. Some of the most clinically significant genes that the test identifies are: BRCA1 and BRCA2, which are genes with known associations to hereditary breast and ovarian cancer syndrome, Lynch syndrome associated genes (MLH1, MSH2, MSH6, PMS2 and EPCAM), CDH1 (mainly associated with hereditary diffuse gastric cancer, and lobular breast cancer), and STK11 (associated with Peutz-Jeghers Syndrome). The risks associated with the test are false positive or false negative test results, as well as possible misunderstanding of the results. False negative test results may provide a false sense of assurance and these patients may not receive appropriate surveillance or clinical management. Breast cancerGenetic diseasesGenetic variantsHematologic tests Next-generation sequencing (Sequencing)Ovarian cancerUnited States Food and Drug Administration Share Facebook Twitter Linkedin ReddIt Email Malorye Branca Also of Interest * News & Features | FDA Begins Program to Speed Up Development of Rare Disease Therapeutics Genetic Variation in MASLD Suggests Precision Treatment Approaches * News & Features | Midline Gliomas Show Immune Response to Novel Vaccine * News & Features | Chromosomal Instability-Caused DNA Damage Increases Cancer Cell Invasiveness * News & Features | Some Women Could Avoid Genetic Counseling Before/After Cancer Genetic Testing * News & Features | COVID-19 Antiviral Molnupiravir Linked to SARS-CoV-2 Mutations LEAVE A REPLY Cancel reply Log in to leave a comment This site uses Akismet to reduce spam. Learn how your comment data is processed. Related Content FDA Begins Program to Speed Up Development of Rare Disease Therapeutics FDA Begins Program to Speed Up Development of Rare Disease Therapeutics Genetic Variation in MASLD Suggests Precision Treatment Approaches Genetic Variation in MASLD Suggests Precision Treatment Approaches Midline Gliomas Show Immune Response to Novel Vaccine Midline Gliomas Show Immune Response to Novel Vaccine Chromosomal Instability-Caused DNA Damage Increases Cancer Cell Invasiveness Chromosomal Instability-Caused DNA Damage Increases Cancer Cell Invasiveness Featured Solutions CentogeneCENTOGENE NEW CentoGenome^(r) [CentoGenom] TECANFluent^(r) Laboratory Automation Workstation [fluent-lab] IlluminaNovaSeq^TM X Plus Sequencing System [hires-nova] ACROBiosystemsCytokine [FP_7] GenomoncologyData Enablement [GenomOncol] Q^2 SolutionsCentral Laboratory Services [Central-La] Featured Solutions CentogeneCENTOGENE NEW CentoGenome^(r) [CentoGenom] TECANFluent^(r) Laboratory Automation Workstation [fluent-lab] IlluminaNovaSeq^TM X Plus Sequencing System [hires-nova] ACROBiosystemsCytokine [FP_7] GenomoncologyData Enablement [GenomOncol] Q^2 SolutionsCentral Laboratory Services [Central-La] Explore * About Us * Contact Us * Advertise * Privacy Policy * Update Preferences Related Sites * Genetic Engineering & Biotechnology News * Genetic Testing & Molecular Biomarkers * OMICS: A Journal of Integrative Biology * Cancer Biotherapy & Radiopharmaceuticals * Big Data * Population Health Management * Telemedicine and eHealth * Clinical OMICs is now Inside Precision Medicine Partnerships A contributing partner: National Society of Genetic Counselors * Terms of Service * Privacy Policy + Cookie Policy * Copyright (c) 2023 Genetic Engineering & Biotechnology News. All Rights Reserved. Inside Precision Medicine MORE STORIES [png] Translating Next-Gen Sequencing from the Lab to the Clinic: Challenges and... April 11, 2014 [png] Next-Gen Sequencing Update April 11, 2014 [png] Super Sequencing Predicts Toxicity of Superbug Strains April 11, 2014